A Proprietary Mammalian Suspension Technology For Scalable rAAV Production: The Pro10™ Cell Line

This paper discusses the Pro10™ cell line, a new technology that improves the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cell line is a proprietary mammalian suspension technology that allows for scalable and robust production of rAAVs, addressing the challenges of large-scale manufacturing in AAV gene therapies. The Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies.

Viralgen uses the Pro10™ cells as the foundation for a robust and scalable rAAV vector manufacturing process. The Pro10™ cells have been optimized for rAAV production and successfully scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. These cells have shown similar productivity in small and large-scale bioreactors and can be used to produce different AAV serotypes. The Pro10™ cells are a crucial component of Viralgen's platform process for manufacturing AAV vectors and have been instrumental in the production of groundbreaking gene therapies.

Access the full PDF where we describe the HEK293 derived animal component-free suspension Pro10™ cell line which can reduce process development time and costs.